USA – Pfizer announced that its respiratory syncytial virus (RSV) vaccine candidate RSVpreF has been designated as a breakthrough therapy by the FDA to prevent RSV-associated lower respiratory tract illness…
Read MorePfizer steps ahead of GSK in race for maternal RSV vaccine
